Omalizumab, Multiallergen OIT Both Viable for Multifood Allergy Treatment

MONDAY, Aug. 3, 2026-- For patients with multifood allergy, treatment success seems higher with omalizumab versus active multiallergen oral immunotherapy (MOIT), but the difference may have been driven by a high rate of study discontinuation by...